Amgen Aktie News

There is always a constant search for dependable prospects that offer stability and advancement. In the middle of this hunt, dividend stocks with growth stand out as possible bright spots that give investors a means to achieve solid returns and reliable income streams.

Dividend investing can be a profitable strategy for traders, providing an extra source of income alongside potential stock gains. Amgen (NASDAQ: AMGN) has demonstrated strong performance, surpassing the average return of the S&P 500.

When the term blue chip is thrown around, many investors hear synonyms like stability and success. Other definitions limit blue-chip stocks to the 30 companies comprising the Dow Jones Industrial Average.

In the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug stocks. Why? Because FDA approval for a drug or treatment can bring years or even decades of steady, high-margin revenue.

Amgen, a leading U.S. biotech company, has outperformed the S&P 500 since 2011. However, the biotech's shares have struggled in 2024.

Delta Air Lines shares could finally take off this year once enough investors can shake off unmerited worries. Drugmaker Amgen's singles and doubles approach to the business makes more sense than always trying for home runs.

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

Planning Underway for Phase 3 Development of Tezepelumab in COPD   THOUSAND OAKS, Calif. , April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic So...